International Clinical Trial: COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449936) titled 'COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME' on Feb. 27.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: EyePoint Pharmaceuticals, Inc.

Condition: Diabetic Macular Edema DME Diabetic Macular Edema (DME)

Intervention: Drug: EYP-1901

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: February 2026

Target Sample Size: 240

Countries o...